Related Experiment Videos
[Cardicap treatment of ischemic heart disease in aged patients]
R M Zaslavskaia1, L F Goncharov, L M Reshniak
1Moscow City Clinical Hospital No 60.
Insights
Cardicap, a new antianginal drug, demonstrated significant effectiveness in improving exercise tolerance and reducing myocardial oxygen demand in patients with ischemic heart disease. This long-acting isosorbide dinitrate formulation showed a notable vasodilating effect over time.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Ischemic heart disease and angina pectoris significantly impact patient quality of life.
- Effective antianginal medications are crucial for managing symptoms and improving outcomes.
Purpose of the Study:
- To evaluate the efficacy of Cardicap, a novel long-acting isosorbide dinitrate formulation.
- To assess the antianginal and vasodilating effects of Cardicap in patients with ischemic heart disease.
Main Methods:
- A study involving 27 patients (mean age 63 years) with ischemic heart disease, class II and III angina pectoris.
- Monitoring included clinical symptoms, exercise tolerance tests, electrocardiogram (ECG), and echocardiography (echo-CG).
Main Results:
- Cardicap exhibited a marked antianginal and vasodilating effect.
- Significant improvements were observed in exercise tolerance.
- A reduction in myocardial power consumption was noted, indicating improved cardiac efficiency.
- The drug's effects were found to be time-dependent.
Conclusions:
- Cardicap is an effective treatment for angina pectoris associated with ischemic heart disease.
- The drug offers a significant improvement in exercise capacity and cardiac efficiency.
- The time-related efficacy suggests sustained benefits with Cardicap use.
Abstract:
The paper presents the results obtained in the study of efficacy of a new antianginal drug cardicap, a long acting isosorbide dinitrate (Natko, India). Changes in the clinical symptoms, exercise tolerance, ECG monitoring and echo-CG parameters in 27 patients (mean age 63 years) with ischemic heart disease, class II and III angina pectoris enable the conclusion on marked antianginal, vasodilatating effect of cardicap, on a rise in the exercise tolerance, reduction in the myocardial power consumption. The effect of cardicap was time-related.